Semaglutide reduces the risk of heart attack, stroke, and other major cardiac events. | Drug Discovery And Development ...

OrsoBio, Inc. ("OrsoBio" or "the Company"), a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic disorders, today announced the presentation of new ...

New clinician-guided program blends medical science, microdosing, and 24/7 support to make advanced weight loss and wellness ...

But does starting Ozempic really throw off birth control? “I'm not aware of any publications that actually report changes in pregnancy rates themselves,” says Jessica Skelley, a pharmacist at Samford ...

People looking to lose weight and lower their blood sugar may someday be able to get a single injection that turns their ...

Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea’s next-generation, ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics ...

A comprehensive review in The Journal of Clinical Investigation finds no overall link between GLP-1 receptor agonists and ...

Scientists from Laval University and the University of Texas Southwestern Medical Center have joined forces to understand ...

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present poster presentations at ObesityWeek® 2025, taking place ...

The Rise Of GLP-1 Drugs In just three years, drugs like Ozempic have reshaped how society views the body. They reignited a ...

MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will present new Phase 1 and pre-clinical data on DA-1726, a novel, dual ...